Charles Schwab’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.13M | Buy |
305,660
+46,123
| +18% | +$925K | ﹤0.01% | 2247 |
|
|
2025
Q1 | $5.11M | Sell |
259,537
-2,351
| -0.9% | -$46.3K | ﹤0.01% | 2260 |
|
|
2024
Q4 | $5.89M | Buy |
261,888
+6,611
| +3% | +$149K | ﹤0.01% | 2263 |
|
|
2024
Q3 | $6.52M | Buy |
255,277
+24,043
| +10% | +$614K | ﹤0.01% | 2235 |
|
|
2024
Q2 | $5.4M | Buy |
231,234
+72,199
| +45% | +$1.69M | ﹤0.01% | 2326 |
|
|
2024
Q1 | $2.8M | Buy |
159,035
+595
| +0.4% | +$10.5K | ﹤0.01% | 2497 |
|
|
2023
Q4 | $2.19M | Buy |
158,440
+1,809
| +1% | +$25K | ﹤0.01% | 2588 |
|
|
2023
Q3 | $2.14M | Buy |
156,631
+94,169
| +151% | +$1.29M | ﹤0.01% | 2574 |
|
|
2023
Q2 | $1.27M | Buy |
+62,462
| New | +$1.27M | ﹤0.01% | 2683 |
|
|
2023
Q1 | – | Sell |
-2,880
| Closed | -$47.1K | – | 3561 |
|
|
2022
Q4 | $47.1K | Buy |
+2,880
| New | +$47.1K | ﹤0.01% | 3371 |
|
|
2021
Q3 | – | Sell |
-4,571
| Closed | -$145K | – | 3514 |
|
|
2021
Q2 | $145K | Sell |
4,571
-3,867
| -46% | -$123K | ﹤0.01% | 3279 |
|
|
2021
Q1 | $285K | Sell |
8,438
-349
| -4% | -$11.8K | ﹤0.01% | 3256 |
|
|
2020
Q4 | $775K | Buy |
8,787
+810
| +10% | +$71.4K | ﹤0.01% | 2849 |
|
|
2020
Q3 | $650K | Sell |
7,977
-199
| -2% | -$16.2K | ﹤0.01% | 2805 |
|
|
2020
Q2 | $904K | Buy |
+8,176
| New | +$904K | ﹤0.01% | 2652 |
|